ArisGlobal Launches XDI

Why It Matters

By converting siloed data into auditable, cross‑domain intelligence, XDI can cut compliance costs and accelerate drug safety decisions, giving life‑science firms a competitive edge.

Key Takeaways

• Federated data layer eliminates need for single data warehouse
• Up to 80% compliance effort reduction across domains
• Benefit‑risk signal detection speeds improve by over 30%
• AI governance ensures regulator‑defensible decisions
• Continuous quality checks remove up to 75% manual QC

Pulse Analysis

Life‑science companies have long wrestled with data silos spread across clinical, regulatory, and safety systems. Traditional approaches force organizations to consolidate disparate datasets into a single warehouse, a costly and time‑consuming effort that often delays insight generation. XDI sidesteps this bottleneck by federating meaning across existing repositories, allowing analytics to run where the data lives. This architecture not only preserves data provenance but also enables real‑time, cross‑domain reasoning that scales with the growing volume of digital exhaust generated by modern drug development pipelines.

The practical impact of XDI is most evident in three core operational domains. In pharmacovigilance, the solution claims 70‑80% reduction in compliance effort and up to 75% elimination of manual quality checks, shifting teams from reactive incident handling to proactive risk mitigation. Benefit‑risk intelligence gains a 30% faster signal detection rate and compresses cycle times from weeks to days, while regulatory teams benefit from continuous, auditable insights that streamline submissions. These efficiency gains translate directly into lower operating costs, faster time‑to‑market, and stronger safety profiles—critical differentiators in a highly regulated industry.

Underlying XDI’s capabilities is ArisGlobal’s “Trust by Design” framework, which embeds AI governance, auditability, and industry‑specific compliance controls into every layer of the platform. By integrating NavaX AI governance, the system ensures that every recommendation is traceable and defensible before regulators. This focus on responsible AI not only mitigates legal risk but also builds confidence among stakeholders demanding transparent, explainable decision‑making. As AI adoption matures across life sciences, solutions like XDI that combine federated intelligence with robust governance are poised to become the new standard for operational excellence and competitive advantage.